Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Prothena

DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena's clinical stage antibody PRX004 and broader ATTR amyloidosis programme.

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme

AbbVie

ABBV vs. NVO: Which Stock Is the Better Value Option?

Walmart

Eli Lilly

Sanofi

The discount chain's private label sells at prices more than 50% lower than brand names made by Lilly, Sanofi, and Novo Nordisk.

Now on Sale at Walmart: Insulin That's Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk

Walmart Inc (NYSE: WMT) is launching its first-ever private label insulin analog, available exclusively at its stores. The company worked directly with manufacturer Novo Nordisk A/S (NYSE: NVO) on ReliOn Novolog, allowing it to offer the product in both vials and FlexPens at a far lower price.

Walmart, Novo Nordisk Unveil Own Low-Cost Brand Insulin

Novo Nordisk A/S (NYSE: NVO) announced data from SUSTAIN FORTE Phase 3b trial comparing semaglutide 2.0 mg versus 1.0 mg dose as an add-on to metformin in type 2 diabetes in need of additional blood sugar reduction. The results were presented at the Annual Scientific Sessions of the American Diabetes Association, and the preliminary results will be published in The Lancet Diabetes & Endocrinology.

Novo Nordisk's Higher Dose Of Semaglutide Trumped 1-mg Predecessor On Blood Sugar, Weight Reduction

Bagsv æ rd , Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic® (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic® 1.0 mg1. These data were the outcome of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic® 1.0 mg as add-on to metformin with or without sulfonylureas in 961 adults with type 2 diabetes in need of additional blood sugar reduction. The results were presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA)1, 2 and primary results are in press for publication in The Lancet Diabetes & Endocrinology.

Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial

A new FDA-approved product with the potential to triple weight loss in obesity patients should be a huge win for the company.

This Leading Healthcare Company's New Obesity Treatment Has Great Potential

The investment arm of Novo Nordisk AS (NVO) just added to its long list of life science companies, thrusting the Danish pharma giant into the growing market for diagnostics. Novo paid $563 million to become the majority shareholder of U.K.-based BBI Group, a world leader in producing diagnostic reagents and supplies for other test makers.

Novo Nordisk Makes Big Move Into Diagnostics With $563 Million Investment

Privately-held Lumen Bioscience has entered into a research collaboration with Novo Nordisk A/S (NYSE: NVO) to evaluate the use of Lumen's spirulina-based drug development and manufacturing platform in Novo Nordisk's R&D activities within obesity and other metabolic disorders. The initial stages of the research collaboration will take place over approximately one year.

Novo Nordisk, Lumen Bioscience Collaborate For Oral Biologics For Cardiometabolic Diseases

Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.

Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity

Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain overweight people and should be used in conjunction with diet and exercise, Novo Nordisk said in a statement.

Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity

Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.

Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment

Novo Nordisk A/S (NYSE: NVO) has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg.  Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.

Novo Nordisk Resubmits Semaglutide 2mg For Type 2 Diabetes In US

Bagsværd, Denmark, 28 M ay 202 1 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10 months.

Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval

This stock could be a great addition to any long-term portfolio.

Why Novo Nordisk Is Still a Top Stock for 2021

Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) are testing unique weight-loss drugs aimed at tackling the growing problem of obesity and beefing up the top and bottom lines of both pharmaceutical giants.

Novo Nordisk, Eli Lilly Obesity Drugs Could Be Game Changers

Bagsværd, Denmark, 7 May 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme

Which diabetes drug maker will win this photo finish for investors?

These Top 2 Healthcare Companies Are in a Race to Riches

Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q1 2021 Results - Earnings Call Transcript

Denmark's Novo Nordisk A/S (NYSE: NVO) raised its financial forecast after reporting strong first-quarter sales and earnings. The company says the sales were still hit by the effect of patients and wholesalers stocking up on drugs last year in preparation for the COVID-19 pandemic, inventory changes, and the timing of shipments had offset that in the first quarter.

Novo Nordisk's Q1 Sales Buoyed By GLP-1 Products, Lifts FY21 Guidance

Denmark's Novo Nordisk, the world's biggest manufacturer of diabetes drugs, raised its financial forecast in local currencies on Wednesday after reporting first quarter sales and earnings above expectations.

Novo Nordisk ups guidance after Q1 results beat expectations

Financial report for the period 1 January 2021 to 31 March 2021

Novo Nordisk's net profit increased by 6% in the first three months of 2021

Novo Nordisk is the biggest producer of antidiabetic pharmaceuticals in the world. The company is set to report first quarter results on May 5 and analysts are expecting very modest growth.

Profitability Measurements Only One Of Many Attractions For Novo Nordisk

Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.

Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity

Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg.

News for Novo Nordisk Stock (NVO)